SynthesisCancer imaging : the official publication of the International Cancer Imaging Society2025
Prognostic significance of
Synthesis in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Whole-Body PSMA-PET/CT dataset with manually annotated tumor lesions.Scientific data · 2026Article
- Surgery confers survival benefit in De Novo metastatic soft tissue sarcoma patients with low Ki67 or low total lesion glycolysis: a combined PET/CT and clinicopathological analysis.European radiology · 2026Article
- The FAP-FDG Integration Score (FFIS): Development and prognostic validation of a dual-tracer PET phenotype for solid tumors.European journal of nuclear medicine and molecular imaging · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of
objectivesThis meta-analysis aimed to systematically evaluate the prognostic significance of
designThis study is a systematic review and meta-analysis. DATA SOURCES AND
methodsA literature search was conducted in PubMed, Embase, and the Cochrane Library for relevant studies up to January 1st, 2024. Studies exploring the association of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) with overall survival (OS) and progression-free survival (PFS) in STS were included. Pooled hazard ratio (HR) with 95% confidence interval (CI) was calculated using random-effects models.
resultsNineteen studies with 962 patients were included in our meta-analysis. Among these, 16 studies evaluated the correlation between the SUVmax and OS, 10 studies assessed the relationship between MTV and OS, 9 studies examined the association of TLG with OS, and 8 studies investigated the prognostic value of SUVmax in relation to PFS. The pooled HRs of SUVmax, MTV, and TLG for OS were 1.17 (95% CI: 1.07-1.27),1.87 (95% CI: 1.16-3.03), and 2.00 (95% CI: 0.99-4.01), respectively. For PFS, the pooled HR of SUVmax was1.62 (95% CI: 1.14-2.31).
conclusionThis meta-analysis indicates that the metabolic parameter SUVmax derived from
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.